Dare Bioscience, Inc. rose 4.37% in premarket trading, following Maxim's upgrade of the company to "Buy" from "Hold." The upgrade reflects the company's commitment to advancing products for women's health, including its FDA-approved product XACIATO and its various clinical and pre-clinical stage programs.
Comments
No comments yet